News

Engineering Better Healthcare: The Vital Role of Usability Testing and HFE/UE in Medical Device Development

As the MedTech markets expand globally, the need for user-centered design has never been greater. According to the FDA, human factors engineering (HFE) and usability engineering (UE) focus on studying how people interact with technology and how user interface design impacts medical device interactions.

Published on:
October 16, 2024

This article was originally published in Medical Device News Magazine.

Both HFE and UE are based on the international usability standards IEC 62366-1 and IEC 62366-2 with consideration of risk management (ISO 14971). By planning and integrating usability testing for human interaction with medical device technology throughout the device lifecycle and risk management processes, HFE/UE ensures that medical devices meet the complex needs of healthcare professionals and patients, and that user-related and use-related risks are eliminated or mitigated.

Consequently, usability and HFE processes play a pivotal role in ensuring medical devices are safe, effective, and user-friendly. Only by identifying and integrating relevant human factors early in the design process can medical device engineers make informed design decisions regarding ergonomics, materials, and labeling.

The importance of usability and HFE in medical device design

Usability and Human Factors Engineering (HFE) in healthcare is not a recent requirement, but its importance has grown alongside technological innovations and the increasing complexity of interactions and use scenarios of medical devices, which can be more error-prone without meticulous design. An early empirical example of the effectiveness of usability and HFE in healthcare was seen in the redesign of a patient-controlled analgesia (PCA) pump’s user interface (Lin et al., 1998). The study showed reduced programming time, decreased mental workload, and fewer errors, highlighting the practical benefits of HFE in medical equipment design.

Usability and HFE considerations encompass three primary components: device users (e.g., nurse, professional caregiver, etc.), device use environments (hospital, home, etc.), and device user interfaces (visual displays, alarms, etc.). The concept of user-centered design is a strategic approach to design development that aims to place the end-user at the center of the design process and simulate real-life use scenarios to effectively identify usability issues.

Ultimately, the overall usability goal is to prioritize designing systems around people’s tasks and work, thereby minimizing human errors. To achieve this, manufacturers must first perform one or more formative usability evaluations (exploratory studies) of the reasonably foreseeable hazard-related use scenarios to explore and understand user interface design strengths, weaknesses, needs, pain points, and unanticipated use errors. Engaging with potential users such as healthcare professionals and patients can provide valuable insights for design decisions. Formative usability evaluations should be conducted during the development phases (concept generation phase) and are understood as development-accompanying evaluations of the user-product interface. At the end of design development (design validation), summative usability testing must be conducted to demonstrate that the device is safe for use by its intended users. Such summative usability testing should involve the intended users under realistic conditions and may be combined with clinical testing. This proactive approach to formative and summative usability testing (human factors studies) diminishes the necessity for extensive redesigns, thereby enhancing the probability of successful design development. By doing so, it saves valuable time and resources while optimizing human performance, ensuring that medical devices operate safely and effectively in their intended use environments. It is crucial that usability evaluations are conducted by teams that include engineers, designers, HFE specialists, and clinical experts. This multidisciplinary approach ensures feedback from all involved parties and integrates these diverse perspectives into the design and risk management processes.

However, usability does not stop after design development; it applies throughout the entire product development process and may include post-market evaluations for identifying design flaws or confirming adequate usability for design changes.

Balancing common usability elements and regulatory requirements

While the fundamental usability goals of improving safety and effectiveness are widely harmonized, regulatory bodies in various regions may emphasize specific usability or HFE guidelines or have unique interpretations and priorities. For example, China’s NMPA guidelines now align with the US-FDA recommended minimum of 15 users per group. Additionally, the approach and methods align with those recommended by the FDA and in IEC 62366-1 in the US and EU. However, testing in China mandates the use of Chinese for instructions and labeling, whereas English suffices in the US, and national member state languages (>20) are required in most countries of the EU. Therefore, depending on the users (specifically for lay users) and use scenarios, planning for multilingual testing may become essential during summative evaluations, not only to develop safe-to-use devices but also to meet basic regulatory requirements.

Regulatory submissions in the US, EU, the UK, and China necessitate formative usability evaluations and summative usability testing with a specified number of users in the intended use environments. This testing must be conducted with the final product design as part of the design validation. If not planned and carried out methodically throughout the design phases, the process of planning, selecting appropriate users (participants), testing, and providing comprehensive analysis and feedback into design as well as risk management documents can be time-consuming and expensive. Quite often, during reviews from authorities or Notified Bodies, documentation for usability is found to be inadequate, resulting in a non-conformity being raised, which often consequently requires re-testing or halting marketing. Therefore, manufacturers should carefully pay attention to these fundamental usability requirements to ensure regulatory compliance and ease of market success. Manufacturers aiming to sell across multiple regions and potential region-specific differences are recommended to familiarize themselves with relevant HFE standards and guidelines and to integrate these requirements early in the design process before starting usability testing.

Conclusion

Medical devices should be designed and developed to be safe and effective. The implementation and use of an adequate usability or HFE process is not only a reasonable way to make design development and risk management more efficient, but it is also a regulatory requirement for medical device manufacturers in most regions, and is increasingly reviewed during submissions by regulatory bodies. Regulators worldwide have harmonized the requirements for usability and use or refer to the international standard IEC 62366-1. This standard provides excellent guidance on how to implement formative and summative usability testing in the design development process. To confirm regulatory compliance in these markets, additional HFE guidelines that are specific to certain regions must also be followed. This is significant because these standards and guidelines are frequently the only basis for interpretation and expectations from regulators and reviewers. It might be acceptable for manufacturers to employ alternative techniques if they do not adhere to them closely enough, but doing so could also lead to serious concerns during regulator reviews. A thorough understanding and proper application of usability and HFE, along with their integration with risk management, are crucial for the entire design team in medical device companies. These elements form the foundation for developing safe and effective medical devices efficiently.

Editor’s note:  Oliver Eikenberg brings over 14 years of extensive experience in the medical device industry, covering R&D, manufacturing, QC, and product management, alongside 15 years in regulatory and quality affairs consulting. His expertise spans EU, US, and Australian regulations. Oliver has specialized expertise in IVD genetic tests, Companion Diagnostics, in-house tests (LDTs) and clinical performance studies and interaction with Notified Bodies and Competent Authorities.

Subscribe to newsletter
Subscribe to receive the latest blog posts to your inbox every week.
By subscribing, you agree to our Terms and Conditions.
Thank you for subscribing!
Oops! Something went wrong while submitting the form.
Read more

Latest News

Browse our news hub featuring company announcements, regulatory updates, and industry insights to keep you informed and ahead of the curve.

Regulatory Update
March 6, 2025

In this week's update, we cover highlights from The EMDN Working Group's November 2024 meeting, which includes important developments in medical device nomenclature.

Regulatory Update
February 19, 2025

This week in global medical device news: Brazil's ANVISA goes 100% digital, more Approved Bodies in the UK, revised guidance on HIV self-test kits in Malaysia, and more.

Regulatory Update
February 12, 2025

The fifth revision to the EU's guidance on Notified Body requirements under the MDR and IVDR has been released. Canada published new guidance on machine learning-enabled devices, findings from China's Medical Device Standards Management Annual Report, and more in this week's round-up of medical device regulatory news.

Regulatory Update
February 5, 2025

To close out January 2025, we are reporting on medical device regulatory developments in the European Union and Switzerland, including IVDR compliance challenges cited in the MedTech Europe 2024 Regulatory Survey, as well as guidance, FAQ, and form updates from Swissmedic.

Contact us
Request information

Let's Talk,
Anywhere You Are.

Whether looking for more information or ready to partner with us, we're here to guide you through every step of the regulatory process.

Our closest representative will get back to you within 24 hours.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Latest Blog Content

Explore our collection of articles, success stories, and regulatory updates, designed to help you take your product global.

RIVM report: The impact of the new European IVD-classification rules on notified body involvement A study on IVDs registered in the Netherlands
Blog Article

The IVDR transition includes structured processes IVD manufacturers must follow to engage with Notified Bodies. Many IVD manufacturers are interacting with Notified Bodies for the first time and must understand what is required to ensure a successful partnership. In this article, Dr. Oliver Eikenberg clarifies what manufacturers must prepare and when to engage a Notified Body for IVDR CE Marking.

Blog Article

Class D IVD manufacturers face fast-approaching IVDR transition deadlines, though some are more familiar with the regulatory process. In this article, Dr. Oliver Eikenberg discusses the difference between "new" and "old" Class Ds, and regulatory logistics they need to consider during the transition process.

Blog Article

Your IVD's intended purpose determines its classification, clinical evidence requirements, and clinical applications under the IVDR. Device companies will need a more robust intended purpose to fulfill IVDR criteria. In this article, Dr. Oliver Eikenberg explains the role of the intended purpose in IVDR compliance.

Blog Article

Many IVD and legacy IVD device manufacturers are obligated to comply with certain aspects of the IVDR even before their transition deadline. In this article, Oliver Eikenberg discusses how IVD companies can maintain EU compliance during the transition period.